Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DDB2
REST API REST API
Homo sapiens
DDB2 is differentially expressed in 301 experiments: 121 organism parts: cerebellum, cervix, ... (119 more);, 153 disease states: normal, glioblastoma, ... (151 more);, 89 cell types 358 cell lines 49 compound treatments and 64 other conditions.
Synonyms UV-DDB2, FLJ34321, DDBB
Orthologs DDB2_BOVIN (Bos taurus)   ddb2 (Danio rerio)   Ddb2 (Mus musculus)   DDB2_CHICK (Gallus gallus)   LOC100362121 (Rattus norvegicus)   ddb2 (Xenopus laevis)   DDB2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, DNA binding, nucleotide-excision repair, protein binding, protein autoubiquitination, DNA repair, damaged DNA binding, protein complex, nucleus, protein polyubiquitination, ubiquitin-protein ligase activity, nucleoplasm, pyrimidine dimer repair, nucleotide-excision repair, DNA damage removal
InterPro Term WD40_repeat_dom, WD40_repeat, WD40_repeat_2, WD40_repeat_subgr
UniProt Accession Q92466
Gene-Disease Assocation XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E
Search EB-eye ENSG00000134574
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
HCC2157
2
E-MTAB-37, E-MTAB-62
HT1080
2
E-MTAB-37, E-GEOD-20089
MCF7
2
E-GEOD-5258, E-MTAB-37
352 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (44 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
not specified
2
E-GEOD-18811, E-GEOD-11755
BDCA3+ dendritic cell
1
E-TABM-34
CD34+ hematopoietic progenitor cell
1
E-GEOD-19240
basal cell
1
E-GEOD-3998
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-12254, E-GEOD-16363, E-GEOD-3678, ... (58 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-GEOD-4412, E-MTAB-62, E-GEOD-6014
prostate carcinoma
4
E-GEOD-96, E-MTAB-62, E-MEXP-2034, E-MEXP-1327
control
3
E-GEOD-21912, E-GEOD-20602, E-GEOD-16363
uterine fibroid
3
E-MTAB-62, E-GEOD-7307, E-GEOD-2724
dermatomyositis
2
E-GEOD-1551, E-MTAB-62
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
147 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (29 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5824, E-TABM-868, E-MEXP-1230, E-GEOD-5230, E-MEXP-1958, ... (9 experiments)
control
2
E-GEOD-995, E-GEOD-3284
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
mercaptopurine, methotrexate
1
E-GEOD-412
CNOT7+CNOT8
1
E-MEXP-2218
NaOH
1
E-MEXP-2590
43 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-GEOD-4667, E-MEXP-2283 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-TABM-26, E-TABM-147, E-GEOD-21138, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-22593, E-GEOD-2724, E-TABM-43, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-MEXP-1446, E-GEOD-22278, E-GEOD-9764, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-GEOD-9723, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-22056, E-GEOD-7179

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-6434, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.282 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM